EUVIMEDEUVIMED entdecken
Crossref

Therapeutic Drug Monitoring of Itraconazole in Endemic Paracoccidioidomycosis: Real-World Data

Wdson Luis Lima Kruschewsky, Vera Lucia Teixeira de Freitas, Mariane Taborda, Isabela Antonini Alves Oliveira Quadros, Mônica Scarpelli Martinelli Vidal, Tiago Alexandre Cocio, Gil Benard, Nilo José Coêlho Duarte, Vítor Falcão de Oliveira, Adriana Satie Gonçalves Kono Magri, Marcello Mihailenko Chaves Magri

Mycopathologia · 2026

DOI: 10.1007/s11046-025-01032-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mycopathologia, 2026. Verfasst von Wdson Luis Lima Kruschewsky und 10 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases and Tropical Medicine Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.…. Hauptthemen laut MEDLINE: Itraconazole, Paracoccidioidomycosis, Drug Monitoring, Antifungal Agents. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Therapeutic drug monitoring (TDM) of itraconazole (ITC) has been recommended by international guidelines to optimize efficacy and reduce toxicity, especially in the context of invasive fungal infections. However, whether the same therapeutic targets apply to paracoccidioidomycosis (PCM) remains uncertain. METHODS: We conducted a retrospective analysis of patients with proven or probable PCM who used ITC during antifungal treatment between 2016 and 2024 at the University of São Paulo. Two groups were formed: the TDM group and the non-TDM group. Serum samples were obtained at steady-state (≥ 7 days after treatment initiation), and ITC levels were measured by liquid chromatography-mass spectrometry (LC-MS/MS). The institutional standard treatment was ITC capsules at 200 mg once or twice daily, depending on disease severity. Therapeutic serum trough concentrations were defined as 0.5-4.0 mg/L. RESULTS: Eighty-three patients were included, 18 in the TDM group and 65 in the non-TDM group, predominantly middle-aged males (median age 53 years; 70% male) with the chronic form of PCM (84%). Only 44.4% of initial serum concentrations were within the therapeutic range. Notably, 22% of patients had undetectable serum levels (< 0.014 mg/L). The median ITC concentration was 0.26 mg/L (IQR 0.04-1.95), and no toxic levels were observed. No statistically significant differences were found between the groups regarding ITC dose modification, drug interactions, toxicity, or duration of therapy. CONCLUSION: Subtherapeutic serum ITC concentrations were common among PCM patients receiving capsule formulations. Although clinical response was generally favorable, the high variability in absorption highlights the potential value of TDM in selected cases. Prospective studies are warranted to define optimal target levels for PCM management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ItraconazoleParacoccidioidomycosisDrug MonitoringAntifungal AgentsHumansMaleMiddle AgedRetrospective StudiesFemaleAdultAgedTandem Mass SpectrometryChromatography, LiquidBrazilYoung AdultEndemic Diseases

Stichwörter der Autor:innen

Antifungal therapyItraconazoleParacoccidioidomycosisTherapeutic drug monitoring

Substanzen

ItraconazoleAntifungal Agents

Autor:innen und Institutionen

  • Infectious Diseases and Tropical Medicine Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. wdsonkruschewsky@gmail.com.
  • Laboratory of Medical Imunology-LIM48, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Instituto de Medicina Tropical, São Paulo, Brazil.
  • Infectious Diseases and Tropical Medicine Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Laboratory of Medical Mycology-LIM53, Instituto de Medicina Tropical/Division of Clinical Dermatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Central Laboratory Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Instituto Do Câncer Do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

Zitieren

APA

Kruschewsky, W. L. L., de Freitas, V. L. T., Taborda, M., Quadros, I. A. A. O., Vidal, M. S. M., Cocio, T. A., Benard, G., Duarte, N. J. C., de Oliveira, V. F., Magri, A. S. G. K., & Magri, M. M. C. (2026). Therapeutic Drug Monitoring of Itraconazole in Endemic Paracoccidioidomycosis: Real-World Data. Mycopathologia. https://doi.org/10.1007/s11046-025-01032-7

Vancouver

Kruschewsky WLL, de Freitas VLT, Taborda M, Quadros IAAO, Vidal MSM, Cocio TA, et al. Therapeutic Drug Monitoring of Itraconazole in Endemic Paracoccidioidomycosis: Real-World Data. Mycopathologia. 2026. doi:10.1007/s11046-025-01032-7

BibTeX
@article{Kruschewsky2026,
  author = {Kruschewsky, Wdson Luis Lima and de Freitas, Vera Lucia Teixeira and Taborda, Mariane and Quadros, Isabela Antonini Alves Oliveira and Vidal, Mônica Scarpelli Martinelli and Cocio, Tiago Alexandre and Benard, Gil and Duarte, Nilo José Coêlho and de Oliveira, Vítor Falcão and Magri, Adriana Satie Gonçalves Kono and Magri, Marcello Mihailenko Chaves},
  title = {Therapeutic Drug Monitoring of Itraconazole in Endemic Paracoccidioidomycosis: Real-World Data},
  journal = {Mycopathologia},
  year = {2026},
  doi = {10.1007/s11046-025-01032-7}
}
Kostenlos starten →